Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Warfarin-Induced Non-Uremic Calciphylaxis Mimicking Vasculitis

Marie Dardeno, DO, Joshua D. Sparling, MD, & William Monaco, MD  |  Issue: May 2021  |  May 13, 2021

Calciphylaxis, or calcific uremic arteriolopathy, is a rare disease characterized by calcification of the arterioles and capillaries in the dermis and subcutaneous tissue, resulting in thrombus formation and subsequent skin ischemia and necrosis.1 This serious condition most commonly occurs in patients with end-stage renal disease (ESRD) requiring dialysis or in kidney transplant recipients. In rare cases, warfarin has been associated with non-ESRD-related calciphylaxis.1

Diagnosis of this disease can be challenging because it can mimic a vasculitis.2 We describe a patient without ESRD but on warfarin who presented with necrotizing skin lesions of unknown etiology and was eventually diagnosed with calciphylaxis. This case proved challenging due to the atypical etiology of this rare disease, its presentation clinically as a vasculitis and the requirement of multiple biopsies for a definitive diagnosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Introduction

Calciphylaxis is classically a disease associated with renal failure, with the majority of patients nearing or on dialysis.2 This condition can also occur without kidney disease, termed non-uremic calciphylaxis, and is most commonly associated with derangements in calcium and phosphate homeostasis, such as hyperphosphatemia, hyper­calcemia and thyroid disease.2 Additionally, cases of exposure to warfarin as a cause for calciphylaxis have been documented.1 Non-uremic calciphylaxis is thought to be a small subset of overall calciphylaxis cases. As of 2016, 116 cases had been identified.3 Warfarin-induced non-uremic calciphylaxis represents an even smaller subset of these cases.

The suspected mechanism by which war­farin induces calciphylaxis is through the inhibition of vitamin K-dependent carbox­ylation of matrix Gla-protein, a mineral-binding extracellular matrix protein that prevents calcium deposition in arteries.4 This leads to progressive narrowing of cutaneous blood vessel lumens through calcification within the media layer of vessel walls and by the proliferation of endothelial cells and fibrosis underneath the intima.2 Thrombosis is the final step in calciphylaxis, which ultimately leads to complete vessel occlusion. Warfarin decreases protein C levels faster than the coagulation factors, therefore increasing thrombus formation.5 Ultimately, with microvascular thrombosis, ischemia develops.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Calciphylaxis often presents as cutaneous lesions of livedo reticularis, plaques, nodules and ulcers due to ischemia of the microvasculature.2 Plaques or nodules are the most common presenting lesions, which may be confused with cellulitis because both lesions can present with erythema, pallor and tenderness.2 Patients may have advanced disease, however, once the diagnosis is officially made.

Case Report

A 77-year-old woman with a past medical history of atrial fibrillation on 5 mg of warfarin daily for over a year and non-biopsy-proven giant cell arteritis on 25 mg of prednisone once a day presented to the dermatology and rheumatology clinics with a four-month history of a worsening reticulated violaceous rash on both her legs (see Figure 1). The rash initially started as a “black scab” on her left mid-shin. However, over the course of a month or so, she developed progressive, escalating pain as the areas of involvement increased in size and severity and, eventually, involved both shins.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:calciphylaxiscase reportEnd-stage renal diseasewarfarin

Related Articles

    Case Report: Refractory Calciphylaxis in Lupus

    May 17, 2018

    Calciphylaxis is a poorly understood and life-threatening ischemic vasculopathy characterized by calcification of the small- and medium-size arteries in the skin, subcutaneous tissue and internal organs, which leads to thrombosis, tissue necrosis and painful skin ulcerations that won’t heal. The disease has a 50–80% mortality rate. Although affected patients typically have end-stage renal disease (ESRD)…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Exploring the Complement System in Human Disease

    February 1, 2010

    Novel disease associations revealed by whole genome screens

    Effects of Warfarin on Risk of Hip & Knee Replacement in OA Patients

    December 4, 2020

    The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences